Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895172 | 0.83 | PIK3CG (0.66) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL24552431 | 0.80 | AHR (0.56) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL24550797 | 0.80 | AHR (0.56) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL353166 | 0.79 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL19086928 | 0.79 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL19597624 | 0.79 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL9304987 | 0.79 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| Zoxazolamine SCHEMBL10891033 | 0.79 | LMNA (1.00) | LMNACYP1A2MAPTTHRBALOX15 | |
| Zoxazolamine SCHEMBL251567 | 0.79 | LMNA (1.00) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL11491925 | 0.79 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688773-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2026-02-11 | — | — | EP | claimed |
| WO-2024201424-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2024-10-03 | — | — | WO | claimed |
| CN-115141192-B | Preparation method of Perilla Wo Leisheng | 杭州国瑞生物科技有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-115141192-A | Preparation method of Su Wo Leisheng | 杭州国瑞生物科技有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-111943945-B | Suvorexant intermediate and preparation method thereof | 上海应用技术大学 | 2022-07-12 | — | — | CN | claimed |
| CN-113880936-B | Solid-phase synthesis method of abamectin | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-108602810-B | Suvorexane intermediate compound and preparation method thereof | 浙江华海药业股份有限公司 | 2021-11-09 | — | — | CN | claimed |
| CN-107021955-B | Suvorexane intermediate compound and preparation method thereof | 上海奥博生物医药股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| EP-3412665-B1 | SUVOREXANT INTERMEDIATES AND PREPARATION METHODS THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2021-03-03 | — | — | EP | claimed |
| CN-111943945-A | Suvorexant intermediate and preparation method thereof | 上海应用技术大学 | 2020-11-17 | — | — | CN | claimed |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-14 | — | — | US | claimed |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-07 | — | — | US | claimed |
| CN-106478537-B | A kind of preparation method of [2- [(the chloro- benzoxazoles -2- base of 5-) (3- oxo butyl) amino] ethyl] t-butyl carbamate | 上海再启生物技术有限公司 | 2019-01-15 | — | — | CN | claimed |
| EP-3412665-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-12-12 | — | — | EP | claimed |
| CN-108602810-A | Su Woleisheng midbody compounds and preparation method thereof | 浙江华海药业股份有限公司 | 2018-09-28 | — | — | CN | claimed |
| CN-107298678-A | A kind of bulk drug Su Woleisheng preparation method | 安徽拜善晟制药有限公司 | 2017-10-27 | — | — | CN | claimed |
| CN-107021955-A | Su Woleisheng midbody compounds and preparation method thereof | 上海奥博生物医药技术有限公司 | 2017-08-08 | — | — | CN | claimed |
| CN-106478537-A | A kind of preparation method of [2 [(5 chlorobenzene diozaiole, 2 base) (3 oxo butyl) amino] ethyl] t-butyl carbamate | 上海再启生物技术有限公司 | 2017-03-08 | — | — | CN | claimed |
| CN-103923068-B | For compound preparing suvorexant and preparation method thereof | 武汉珈瑜科技有限公司 | 2016-09-07 | — | — | CN | claimed |
| CN-103923068-A | Compound for preparing suvorexant and preparation method thereof | WUHAN JIAYU TECHNOLOGY CO LTD | 2014-07-16 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | COMT, KMO, CYP4B1 | LMNA 2166/4885CYP1A2 140/4885MAPT 2399/4885 |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | COMT, KMO, CYP4B1 | LMNA 2166/4885CYP1A2 140/4885MAPT 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.